Edwards Lifesciences officer proposes $48.9K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Edwards Lifesciences Corp officer Andrew M. Dahl reported a proposed sale of 568 common shares, with an aggregate market value of $48,853 and an approximate sale date of May 29, 2026. The notice lists 252 shares acquired through a restricted stock lapse on February 22, 2025, and 316 shares acquired through the Employee Stock Purchase Plan on June 28, 2024. The remarks state that the plan shares were acquired and paid for between June 28, 2024 and March 31, 2025.
Key Figures
Key Terms
Restricted Stock Lapse technical
Employee Stock Purchase Plan financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.